Portal de Periódicos da CAPES

Model‐based approach to dose optimization of lopinavir/ritonavir when co‐administered with rifampicin

2011; Wiley; Volume: 73; Issue: 5 Linguagem: Inglês

10.1111/j.1365-2125.2011.04154.x

1365-2125

Chao Zhang, Paolo Denti, Eric Decloedt, Gary Maartens, Mats O. Karlsson, Ulrika S. H. Simonsson, Helen McIlleron,

Antibiotics Pharmacokinetics and Efficacy

Rifampicin, a key component of antitubercular treatment, profoundly reduces lopinavir concentrations. The aim of this study was to develop an integrated population pharmacokinetic model accounting for the drug-drug interactions between lopinavir, ritonavir and rifampicin, and to evaluate optimal doses of lopinavir/ritonavir when co-administered with rifampicin.